Dr. Brian Skotko and his research team from the MassGeneral Hospital Down Syndrome Program are starting another study drug trial.
In this clinical trial, an investigational medicine, not yet approved for sale by the FDA, will be studied in people with Down syndrome who meet eligibility criteria. This study drug is hoped to improve the cognitive capacities in some people with Down syndrome.
Up until now, opportunities for people with Down syndrome to participate in research have been scant, for a variety of reasons. For the first time, study drug trials are now available to people with Down syndrome. Enhancing the well-being of all people with Down syndrome remains the greatest aim of all of the research opportunities that we offer through the Mass General Hospital Down Syndrome Program.
There are a limited number of spots for this clinical trial, and eligible patients are screened in the order in which they contact us.
This study is being funded by Elan, the developer of the drug in the upcoming study. The upcoming clinical trial will evaluate the safety of the study drug and how it works in the body. The study will take place over 10 weeks and will include 5 clinic visits.
If you would like your family member to participate in this study, or if you have further questions, please contact Mary Ellen McDonough, RN, Senior Clinical research Coordinator in the MassGeneral Hospital Down Syndrome program by calling 617-643-5571 or by emailing her at [email protected]
|